Personalized vaccine boosts immunotherapy in lung cancer trial
NCT ID NCT05886439
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a personalized vaccine called LK101, made from a patient's own tumor markers, combined with standard immunotherapy drugs (pembrolizumab, durvalumab, or tislelizumab) in 60 adults with advanced lung cancer. The goal is to see if the combination is safe and can help control the cancer when previous treatments have stopped working. Participants receive the vaccine as a series of shots plus regular immunotherapy infusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LK101 (personalized cancer vaccine) combined with pembrolizumab, durvalumab, or tislelizumab (immunotherapy drugs)
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced lung cancer that has stopped responding to standard immunotherapy.
- What could go wrong
- This is an early-phase trial with only 60 participants, so results may not apply to everyone. The vaccine is personalized, which makes it complex and costly, and side effects from combining treatments are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?